Omnicell (NASDAQ:OMCL) Upgraded to Buy by BidaskClub
Several other equities research analysts also recently weighed in on the company. ValuEngine downgraded Omnicell from a buy rating to a hold rating in a research report on Monday, December 16th. Wells Fargo & Co upped their target price on Omnicell from $80.00 to $85.00 and gave the stock an equal weight rating in a research report on Wednesday, January 8th. TheStreet raised Omnicell from a c+ rating to a b rating in a research report on Thursday, October 24th. Sidoti set a $82.00 target price on Omnicell and gave the stock a hold rating in a research report on Friday, October 25th. Finally, Cantor Fitzgerald reissued an overweight rating and issued a $95.00 price target (up previously from $91.00) on shares of Omnicell in a report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $84.75.
Shares of NASDAQ OMCL opened at $86.98 on Friday. Omnicell has a 1-year low of $62.40 and a 1-year high of $92.59. The business has a 50-day moving average of $82.26 and a 200-day moving average of $75.85. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.09 and a quick ratio of 1.63. The company has a market capitalization of $3.60 billion, a price-to-earnings ratio of 68.49, a PEG ratio of 2.98 and a beta of 1.12.
In related news, CEO Randall A. Lipps sold 24,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $81.41, for a total value of $1,953,840.00. Following the sale, the chief executive officer now directly owns 116,466 shares in the company, valued at approximately $9,481,497.06. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Scott Peter Seidelmann sold 2,833 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $75.00, for a total value of $212,475.00. Following the completion of the sale, the executive vice president now owns 26,333 shares in the company, valued at $1,974,975. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 59,349 shares of company stock worth $4,743,376. 2.77% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of OMCL. Bank of Montreal Can increased its position in shares of Omnicell by 283.4% during the 2nd quarter. Bank of Montreal Can now owns 6,357 shares of the company’s stock valued at $547,000 after purchasing an additional 4,699 shares during the period. Parametric Portfolio Associates LLC increased its position in shares of Omnicell by 11.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 175,795 shares of the company’s stock valued at $15,124,000 after purchasing an additional 18,304 shares during the period. BlackRock Inc. increased its position in shares of Omnicell by 5.7% during the 2nd quarter. BlackRock Inc. now owns 6,413,649 shares of the company’s stock valued at $551,764,000 after purchasing an additional 344,744 shares during the period. Tower Research Capital LLC TRC acquired a new position in shares of Omnicell during the 2nd quarter valued at $40,000. Finally, Vanguard Group Inc. increased its position in shares of Omnicell by 4.6% during the 2nd quarter. Vanguard Group Inc. now owns 4,223,552 shares of the company’s stock valued at $363,352,000 after purchasing an additional 186,781 shares during the period. Institutional investors own 98.44% of the company’s stock.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Further Reading: Do You Need a Fiduciary?
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.